Recombinant interferon-Beta-1 a plus ribavirin for the treatment of chronic HCV infection: A prospective, randomized, comparative pilot study

Gut and Liver

Volumn 3, Issue 1, 2009, Pages 20-25

  Ahn, Sang Hoon ^a   Lee, Hyun Woong ^b   Kim, Yong Soo ^a   Kim, Ja Kyung ^a   Han, Kwang Hyub ^a,c   Chon, Chae Yoon ^a   Moon, Young Myoung ^a,d  

^a Yonsei University College of Medicine   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c Yonsei University   (South Korea)

^d 131 Shinchon dong ^*  (South Korea)

Author keywords

Hepatitis C; Interferons; Prospective studies; Treatment outcome

Indexed keywords

ALPHA INTERFERON; BETA1A INTERFERON; INTERMAX ALPHA; RIBAVIRIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENOTYPE; GRANULOCYTOPENIA; HAIR LOSS; HEPATITIS C; HUMAN; INSOMNIA; MALE; MOUTH ULCER; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS LOAD; WEAKNESS; WEIGHT REDUCTION;

EID: 67249144306     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2009.3.1.20     Document Type: Article

References (32)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244: 359-362.
2. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002--June 10-12, 2002. Hepatology 2002; 36:S3-20.
3. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9: 331-338.
4. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39: 1147-1171.
5. Myers RP, Regimbeau C, Thevenot T, et al. Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database Syst Rev 2002;(2):CD000370.
6. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 2001; 8: 48-62.
7. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347: 975-982.
8. Pawlotsky JM. Hepatitis C: it's a long way to new therapy, it's a long way to go. Gastroenterology 2004;127: 1629-1632.
9. San Miguel R, Guillen F, Cabases JM, Buti M. Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon. Aliment Pharmacol Ther 2002;16: 1611-1621.
10. Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non-res- ponders to interferon monotherapy: a meta-analysis of individual patient data. Gut 2002;51: 864-869.
11. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237-244.
12. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14: 778-809.
13. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 2000;81: 2341-2364.
14. Kaito M, Yasui-Kawamura N, Iwasa M, et al. Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C. Hepatogastroenterology 2003;50: 775-778.
15. Suzuki F, Chayama K, Tsubota A, et al. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen. J Gastroenterol 2001;36: 242-247.
16. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32: 228-232.
17. Kobayashi Y, Watanabe S, Konishi M, et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Hepatology 1993;18: 1319-1325.
18. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res 2000;20: 857-866.
19. Habersetzer F, Boyer N, Marcellin P, et al. A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C. Liver 2000;20: 437-441.
20. Pellicano R, Craxi A, Almasio PL, et al. Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. World J Gastroentrol 2005;11: 4484-4489.
21. Cheng PN, Marcellin P, Bacon B, et al. Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients. J Viral Hepat 2004;11: 418-426.
22. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005;436: 953-960.
23. Omata M, Yokosuka O, Takano S, et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991;338: 914-915.
24. Barbaro G, Di Lorenzo G, Soldini M, et al. Intravenous re- combinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators. Scand J Gastroenterol 1999;34: 928-933.
25. Perez R, Pravia R, Artimez ML, et al. Clinical efficacy of intramuscular human interferon-beta vs interferon-alpha 2b for the treatment of chronic hepatitis C. J Viral Hepat 1995;2: 103-106.
26. Castro A, Carballo E, Dominguez A, et al. Tolerance and efficacy of subcutaneous interferon-beta administered for treatment of chronic hepatitis C. J Interferon Cytokine Res 1997;17: 65-67.
27. Murdoch D, Lyseng-Williamson KA. Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relaps- ing-remitting multiple sclerosis. BioDrugs 2005;19: 323-325.
28. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004;117: 163-168.
29. Chan HL, Ren H, Chow WC, Wee T; Interferon beta-1a Hepatitis C Study Group. Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C. Hepatology 2007;46: 315-323.
30. Festi D, Sandri L, Mazzella G, et al. Safety of interferon beta treatment for chronic HCV hepatitis. World J Gastroenterol 2004;10: 12-16.
31. Bagheri H, Fouladi A, Barange K, et al. Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy. Pharmacotherapy 2004;24: 1546-1553.
32. Mager DE, Neuteboom B, Jusko WJ. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharm Res 2005;22: 58-61.